High expression of heparanase-2 is an independent prognostic parameter for favorable survival in gastric cancer patients

Cancer Epidemiology

Volumn 37, Issue 6, 2013, Pages 1010-1013

  Zhang, Xiaogang ^a   Xu, Shu ^b   Tan, Qinxiang ^b   Liu, Longgen ^a  

^a Changzhou Wujin People's Hospital   (China)

^b Guangzhou Integrated Traditional and Western Hospital   (China)

Author keywords

Gastric cancer; Heparanase 2; Immunohistochemistry; Prognosis

Indexed keywords

HEPARANASE; HEPARANASE 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TISSUE MICROARRAY; TUMOR VOLUME; WESTERN BLOTTING;

GASTRIC CANCER; HEPARANASE-2; IMMUNOHISTOCHEMISTRY; PROGNOSIS;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POLYSACCHARIDE-LYASES; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84888291239     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.09.012     Document Type: Article

References (21)

1. Vogelaar I.P., van der Post R.S., Bisseling T.M., van Krieken J.H., Ligtenberg M.J., Hoogerbrugge N. Familial gastric cancer: detection of a hereditary cause helps to understand its etiology. Hered Cancer Clin Pract 2012, 10(1):18.
2. Xiong Z., Lü M.H., Fan Y.H., Cao Y.L., Hu C.J., Wu Y.Y., et al. Downregulation of heparanase by RNA interference inhibits invasion and tumorigenesis of hepatocellular cancer cells in vitro and in vivo. Int J Oncol 2012, 40:1601-1609.
3. Wang G.B., Zhou X.Y., Wang X.Q. Relationship between serum heparanase and microscopic venous invasion in patients with hepatocellular carcinoma. Am J Clin Pathol 2010, 134:242-248.
4. Zhang W., Yang H.C., Wang Q., Yang Z.J., Chen H., Wang S.M., et al. Clinical value of combined detection of serum matrix Metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis. Anticancer Res 2011, 31:3423-3428.
5. Cohen E., Doweck I., Naroditsky I., Ben-Izhak O., Kremer R., Best L.A., et al. Heparanase is over-expressed in lung cancer and inversely correlates with patient's survival. Cancer 2008, 113:1004-1011.
6. Meirovitz A., Hermano E., Lerner I., et al. Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma. Cancer Res 2011, 71:2772-2780.
7. Cohen I., Pappo O., Elkin M., San T., Bar-Shavit R., Hazan R., et al. Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer 2006, 118:1609-1617.
8. Barash U., Cohen-Kaplan V., Dowek I., Sanderson R.D., Ilan N., Vlodavsky I. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 2010, 277:3890-3903.
9. Levy-Adam F., Ilan N., Vlodavsky I. Tumorigenic and adhesive properties of heparanase. Semin Cancer Biol 2010, 20:153-160.
10. Vlodavsky I., Goldshmidt O., Zcharia E., Atzmon R., Rangini-Guatta Z., Elkin M., et al. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol 2006, 12:121-129.
11. McKenzie E., Tyson K., Stamps A., Smith P., Turner P., Barry R., et al. Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun 2000, 276:1170-1177.
12. de Moura J.P., Nicolau S.M., Stávale J.N., da Silva Pinhal M.A., de Matos L.L., Baracat E.C., et al. Heparanase-2 expression in normal ovarian epithelium and in benign and malignant ovarian tumors. Int J Gynecol Cancer 2009, 19:1494-1500.
13. Marques R.M., Focchi G.R., Theodoro T.R., Castelo A., Pinhal M.A., Nicolau S.M. The immunoexpression of heparanase 2 in normal epithelium, intraepithelial, and invasive squamous neoplasia of the cervix. J Low Genit Tract Dis 2012, 16:256-262.
14. Xie D., Sham J.S., Zeng W.F., Lin H.L., Che L.H., Wu H.X., et al. Heterogeneous expression and association of beta-catenin,p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 2003, 107:896-902.
15. Vlodavsky I., Beckhove P., Lerner I., Pisano C., Meirovitz A., Ilan N., et al. Significance of heparanase in cancer and inflammation. Cancer Microenviron 2012, 5:115-132.
16. Arvatz G., Shafat I., Levy-Adam F., Ilan N., Vlodavsky I. The heparanase system and tumor metastasis: is heparanase the seed and soil. Cancer Metastasis 2011, 30:253-268.
17. Peretti T., Waisberg J., Mader A.M., de Matos L.L., da Costa R.B., Conceição G.M., et al. Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma. Eur J Gastroenterol Hepatol 2008, 20:756-765.
18. Nobuhisa T., Naomoto Y., Takaoka M., Tabuchi Y., Ookawa K., Kitamoto D., et al. Emergence of nuclear heparanase induces differentiation of human mammary cancer cells. Biochem Biophys Res Commun 2005, 331:175-180.
19. Levy-Adam F., Feld S., Cohen-Kaplan V., Shteingauz A., Gross M., Arvatz G., et al. Heparanase 2 interacts with heparan sulfate with high affinity and inhibits heparanase activity. J Biol Chem 2010, 285:28010-28019.
20. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003, 100:11606-11611.
21. Yu J., Yu J., Rhodes D.R., Tomlins S.A., Cao X., Chen G., et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007, 67:10657-10663.